Former Software Exec Seehafer Is US FDA’s First Deputy Commissioner For Tech And AI
Jared Seehafer has been named the FDA’s first deputy commissioner for technology and artificial intelligence, a role that positions the former compliance software exec to lead the agency’s oversight and deployment of AI and other rapidly evolving technologies.
Medtech Insight - September 8, 2026

Deals Shaping The Medtech And Diagnostics Industries, August 2026
An interactive look at medtech and diagnostics deals made during August 2026. Data courtesy of Biomedtracker.
Medtech Insight - September 8, 2026

PCPC Pays Tribute to Peter Barton Hutt, Architect of US Cosmetics Regulation; Exec Roundup
The Personal Care Products Council said Peter Barton Hutt's enduring legacy will be felt throughout its organization, through the institutions and the industry he helped shape; Executive Roundup
HBW Insight - September 8, 2026

AstraZeneca’s Tozorakimab Positioned For Multi-Billion Opportunity In COPD
The first-in-class IL-33 inhibitor delivered efficacy that out-performed Dupixent in cross-trial comparisons in a broad patient population regardless of blood eosinophil count.
Scrip - September 8, 2026

UK-Based Kneu Health Launches Parkinson’s Disease Monitoring On Apple Watch
Kneu Health‘s passive monitoring tool for Parkinson’s tremor and dyskinesia symptoms is now available via the Apple watch. The integration is intended to help clinicians better manage patients, including through improved symptom tracking between visits.
Medtech Insight - September 8, 2026

Amgen Stands To Broaden Imdelltra Market With First-Line Maintenance ES-SCLC Data
Topline Phase III results for DLL3-inhibiting bispecific Imdelltra plus AstraZeneca’s Imfinzi showed improved survival as a first-line maintenance regimen in extensive-stage small cell lung cancer.
Scrip - September 8, 2026

BMS’s Arlo-Cel Shows Positive Results In BCMA-Exposed Myeloma Patients
The drugmaker announced topline results for the GPRC5D-directed CAR-T cell therapy, not long after winning FDA approval for Zenbexus.
Scrip - September 8, 2026

Financing Quarterly Statistics, Q2 2026
During Q2, biopharmas brought in an aggregate $42.5bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.6bn.
In Vivo - September 8, 2026

If Alexa Won’t Recommend You, ‘You’re Invisible’: How Amazon’s New AI Tool Is Shaking Up OTC
Amazon's integration of AI into its shopping experience is set to fundamentally alter how consumers discover and choose consumer health products. Ross Barber of World Products argues that brands competing only for search rankings are already playing yesterday's game.
HBW Insight - September 8, 2026

Get To Know: Indian Wellness Tech Licensing Specialist Boudhik Ventures
Q&A with Boudhik Ventures director Ishan Tiwari on the Indian firm's mandate-driven model and its push to license Renavita, a patented kidney wellness formulation, in the UK and Europe.
HBW Insight - September 8, 2026

Novartis M&A Strategy Under Spotlight After Another Phase III Blow
The late-stage failures within days of pelacarsen and del-desiran ‘will likely raise questions again about Novartis's due diligence and BD approach,’ analysts at Jefferies have claimed.
Scrip - September 8, 2026

Stock Watch: mRNA’s Cancer Win Puts The Antivax Lobby In a Corner
Weak Q2 vaccine sales across big pharma coincided with rising US antivax sentiment and a presidential order to split the MMR vaccine. But the mRNA vaccine platform demonized by the administration has now posted positive Phase III results in melanoma.
Scrip - September 8, 2026

Fresenius Kabi Latest To Launch Generic Bridion As Merck Prepares US Market Exit
Fresenius Kabi has launched a pre-filled syringe generic sugammadex in the US, as growing generic competition drives Merck to anticipate discontinuing US Bridion sales.
Generics Bulletin - September 8, 2026

Biocon Locks In 10-Year Pertuzumab Opportunity In Brazil
Biocon has secured a 10-year route into Brazil’s public pertuzumab market through a Productive Development Partnership program that combines exclusive access with phased localization and technology transfer for the Perjeta biosimilar.
Generics Bulletin - September 8, 2026

Oncology Trial Waivers In India: Big Pharma, Local Firms Navigate Path To Faster Entry
India's Phase III trial waiver route is gaining traction as foreign and local firms pursue the pathway for oncology drugs even as the regulator continues to draw firm lines on Indian population safety data.
Scrip - September 8, 2026

‘It’s Time To Put The Muttering To Rest’ – Samsung Bioepis Rebuts Biosimilar Drift Concerns
Following the publication of their co-authored journal article on why product drift is not an issue for biosimilars, Samsung Bioepis executives Gillian Woollett and Joseph Park explain why they felt the longstanding issue needed to be put to rest.
Generics Bulletin - September 8, 2026

BrainChild Launches With $116m To Test CAR-T In Pediatric Brain Cancer
BrainChild came out of stealth with $116m in series A cash and CAR-T programs for delivery to the central nervous system, starting with diffuse intrinsic pontine glioma (DIPG).
Scrip - September 8, 2026

Accord Pins Denosumab Launch Delay On Q-Code Timing
Accord says securing a Q-code was the decisive factor behind the delayed US launch of Osvyrti and Jubereq, which reached the market around nine months after a legal sales restriction expired.
Generics Bulletin - September 8, 2026

Roivant’s Mosliciguat Heads To Phase III After 56% PVR Reduction In PH-ILD
The company’s PVR win sets the stage for mosliciguat’s Phase III test, with the company now eyeing a bigger role in PH-ILD.
Scrip - September 8, 2026

Strategic Intent: Evolving Requirements Of Life Sciences Leadership
In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.
In Vivo - September 8, 2026

Novartis Stock Sinks 10% As Del-Desiran Flops In Phase III
It is the second major clinical setback in a week for the Swiss firm after pelacarsen disappointed in a Phase III cardiovascular outcomes study.
Scrip - September 8, 2026

iRhythm To Buy VitalConnect, Plugging 30-Day MCT Gap And Broadening Its Cardiac Monitoring Platform
The $287.5m VitalConnect deal buys iRhythm 20–30% of the mobile cardiac telemetry market that Zio AT cannot serve and leapfrogs its own pre-clearance MCT device. CEO Quentin Blackford said its internal development program will still continue.
Medtech Insight - September 8, 2026